Among CLL/SLL patients who progressed on ibrutinib, mutations in the ibrutinib binding (BTK Cys481), gatekeeper (BTK Thr474), and SH2 (BTK Thr316) domains of BTK have been discovered [110]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.